MedTrace Logo

Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia

NCT04699383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2024-03-18

No results posted yet for this study

Summary

Outcomes of patients receiving SSG and Allopurinol combination have never been documented systematically in Ethiopia. Therefore, it is not known how effective this combination is. This study will provide evidence to help clinicians make the best choice regarding treatment for complicated cutaneous leishmaniasis (CL) cases. Due to diversity in host-pathogen interactions across the different CL forms, early immunological correlates associated with treatment responsiveness and unresponsiveness could help treatment recommendation and provide us with the basis to develop new diagnostic and treatment strategies.

This study aims to document treatment outcomes of patients with cLCL, MCL, and DCL receiving systemic treatment using SSG and Allopurinol combination within a routine care setting located in a highly endemic area in Ethiopia.

Conditions

  • Cutaneous Leishmaniasis

Interventions

DRUG

Sodium Stibogluconate with allopurinol

Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles

Sponsors & Collaborators

  • Wollo University

    collaborator OTHER

  • Boru Meda Hospital

    collaborator UNKNOWN

  • University of Gondar

    collaborator OTHER

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • Ethiopia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04699383 on ClinicalTrials.gov